These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

119 related articles for article (PubMed ID: 7089046)

  • 1. Effects of carbamylation of plasma proteins and competitive displacers on drug binding in uremia.
    Calvo R; Carlos R; Erill S
    Pharmacology; 1982; 24(4):248-52. PubMed ID: 7089046
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Plasma protein carbamylation and decreased acidic drug protein binding in uremia.
    Erill S; Calvo R; Carlos R
    Clin Pharmacol Ther; 1980 May; 27(5):612-8. PubMed ID: 7371359
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Abnormal serum protein binding of acidic drugs in diabetes mellitus.
    Ruiz-Cabello F; Erill S
    Clin Pharmacol Ther; 1984 Nov; 36(5):691-5. PubMed ID: 6488690
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Endogenous accumulation products and serum protein binding in uremia.
    McNamara PJ; Lalka D; Gibaldi M
    J Lab Clin Med; 1981 Nov; 98(5):730-40. PubMed ID: 7299243
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Correction of protein binding defect in uremic sera by charcoal treatment.
    Craig WA; Evenson MA; Sarver KP; Wagnild JP
    J Lab Clin Med; 1976 Apr; 87(4):637-47. PubMed ID: 1270877
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Inability of accumulated metabolic byproducts of uremia to alter the extent of warfarin binding in charcoal treated plasma.
    Bachmann K; Conway P; Shapiro R
    Res Commun Chem Pathol Pharmacol; 1978 Apr; 20(1):117-30. PubMed ID: 663394
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Serum protein binding of sulfisoxazole and diazepam in patients with chronic obstructive pulmonary disease.
    Guerrero J; García-Morillas M; Gil-Extremera B; Erill S
    Int J Clin Pharmacol Ther Toxicol; 1987 May; 25(5):255-8. PubMed ID: 3596851
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Differential effects of hepatic cirrhosis on the plasma protein binding of drugs.
    García-Morillas M; Gil-Extremera B; Caracuel-Ruiz MD
    Int J Clin Pharmacol Res; 1984; 4(5):327-33. PubMed ID: 6519849
    [TBL] [Abstract][Full Text] [Related]  

  • 9. In vitro inhibition of low density lipoprotein carbamylation by vitamins, as an ameliorating atherosclerotic risk in uremic patients.
    Ghaffari MA; Shanaki M
    Scand J Clin Lab Invest; 2010 Apr; 70(2):122-7. PubMed ID: 20156036
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Investigation of the drug-binding defect in plasma from rats with glycerol-induced acute renal failure.
    Bowmer CJ; Lindup WE
    J Pharmacol Exp Ther; 1979 Sep; 210(3):440-5. PubMed ID: 480193
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Protein binding of salicylate in uremic and normal plasma.
    Borgå O; Cederlöf IO; Ringberger VA; Norlin A
    Clin Pharmacol Ther; 1976 Oct; 20(4):464-75. PubMed ID: 975718
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Unchanged protein binding of penbutolol in renal insufficiency: a possible role of carbamylation.
    Aguirre C; Calvo R; Rodriguez-Sasiain JM
    Int J Clin Pharmacol Ther Toxicol; 1993 Jan; 31(1):31-4. PubMed ID: 8444514
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Protein carbamylation links inflammation, smoking, uremia and atherogenesis.
    Wang Z; Nicholls SJ; Rodriguez ER; Kummu O; Hörkkö S; Barnard J; Reynolds WF; Topol EJ; DiDonato JA; Hazen SL
    Nat Med; 2007 Oct; 13(10):1176-84. PubMed ID: 17828273
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Carbamylation of erythrocyte membrane proteins: an in vitro and in vivo study.
    Trepanier DJ; Thibert RJ; Draisey TF; Caines PS
    Clin Biochem; 1996 Aug; 29(4):347-55. PubMed ID: 8828965
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Procaine hydrolysis defect in uraemia does not appear to be due to carbamylation of plasma esterases.
    Calvo R; Carlos R; Erill S
    Eur J Clin Pharmacol; 1983; 24(4):533-5. PubMed ID: 6861870
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Isolation of peptides from uremic plasma that inhibit phenytoin binding to normal plasma proteins.
    Kinniburgh DW; Boyd ND
    Clin Pharmacol Ther; 1981 Aug; 30(2):276-80. PubMed ID: 7249510
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Valproate plasma protein binding in the uremic condition.
    Brewster D; Muir NC
    Clin Pharmacol Ther; 1980 Jan; 27(1):76-82. PubMed ID: 6985855
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Acetaldehyde adducts with serum proteins: effect on diazepam and phenytoin binding.
    Lucas D; Ménez JF; Daniel JY; Bardou LG; Floch HH
    Pharmacology; 1986; 32(3):134-40. PubMed ID: 3960964
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Biophysical studies on the correction of uremic human serum albumin binding defects by in vitro charcoal adsorption treatment.
    Nikolaev V; Sarnatskaya V; von Appen K; Ivanov A; Rotellar E; Haspar M; Klinkmann H
    Artif Organs; 1996 Jan; 20(1):17-23. PubMed ID: 8645124
    [TBL] [Abstract][Full Text] [Related]  

  • 20. PON-1 carbamylation is enhanced in HDL of uremia patients.
    Chang CT; Lim YP; Lee CW; Liao HY; Chen FY; Chang CM; Tang FY; Yang CY; Chen CJ
    J Food Drug Anal; 2019 Apr; 27(2):542-550. PubMed ID: 30987726
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.